Ranibizumab 0.5mg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Drug Information

Target Indication

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Clinical Trial

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Neovascular Age-related Macular Degeneration

Renal Interstitial Fibrosis

Pathological Myopia

Non-Small Cell Lung Cancer

Prostatic Neoplasms